For more than two decades, Dexcom has focused on helping people manage diabetes through continuous glucose monitoring. Its sensors are now used by millions of people worldwide and play an increasingly important role in diabetes management, particularly as hybrid-closed loop systems become more widely available.
This week, however, the company announced a move that suggests its ambitions extend well beyond diabetes alone.
Dexcom has entered into an agreement to acquire Nutrisense, a US-based platform that combines CGM data with nutrition coaching, registered dietitians and personalised metabolic health guidance. The transaction is expected to close in the coming weeks, subject to customary approvals.
While the acquisition may initially appear to be a straightforward expansion of Dexcom's business, it also provides one of the clearest indications yet of where the company believes glucose monitoring is heading next.
Rather than focusing solely on helping people manage diabetes, Dexcom is increasingly positioning CGM as a tool that can support nutrition, behaviour change, preventative care and broader metabolic health.
What is Nutrisense?
Nutrisense has become one of the most recognised names in the rapidly growing metabolic and wellbeing health market.
The platform combines CGM data with meal tracking, exercise logging and support from registered dietitians. Users receive personalised guidance designed to help them understand how food, activity, sleep and other lifestyle factors influence blood sugar levels.
Although many Nutrisense users live with diabetes or prediabetes, the platform has also attracted growing interest from people focused on weight management, fitness, nutrition and overall health.
That broader audience is significant because it reflects a growing belief across the industry that glucose data may have value beyond traditional diabetes care.
Unlike most CGM manufacturers, Nutrisense has built its business around helping people interpret glucose information and turn it into practical actions. That expertise appears to be a major part of what attracted Dexcom to the company.
Dexcom already provides the data. Nutrisense provides the interpretation.
Dexcom's core strength has always been the sensor itself.
Over the years the company has invested heavily in improving accuracy, connectivity, wearability and integration with insulin pumps and hybrid-closed loop systems. As a result, Dexcom has become one of the largest and most influential CGM manufacturers in the world.
However, collecting glucose data is only part of the picture.
A CGM can show what blood sugar levels are doing throughout the day, but it cannot always explain why those changes are happening or what adjustments may help. Understanding the relationship between food, exercise, sleep and glucose patterns often requires additional support.
According to Dexcom, the acquisition will strengthen its ability to provide personalised nutrition education, behaviour-change support and guidance that links food choices directly to glucose responses.
In practical terms, the deal signals a move beyond simply measuring glucose and towards helping users better understand and act on the information their CGM provides.
This wasn't the only announcement
The acquisition was announced as part of Dexcom's presence at the American Diabetes Association's Scientific Sessions (ADA 2026).
Alongside the Nutrisense deal, the company also unveiled a redesigned Stelo experience. Stelo is Dexcom's over-the-counter CGM platform aimed at adults with type 2 diabetes who are not using insulin, as well as people interested in understanding their metabolic health.
The updated platform introduces AI-powered coaching, pattern recognition, personalised summaries and more detailed insights designed to help users understand trends in their glucose data.
Viewed in isolation, each announcement is noteworthy and taken together, they reveal a much broader strategy centred on helping people understand and respond to health data rather than simply collecting it.
Why now?
The timing of the acquisition is unlikely to be accidental.
Over the past decade, CGM adoption among people with type 1 diabetes has increased dramatically. In England alone, more than 380,000 people now use FreeStyle Libre systems through the NHS, while Dexcom use has also continued to grow.
As access expands and diabetes markets mature, manufacturers are increasingly looking at where the next phase of growth will come from.
For Dexcom, that opportunity appears to include people with type 2 diabetes who are not using insulin, earlier intervention in diabetes care, personalised health coaching and broader metabolic health services.
The acquisition of Nutrisense fits squarely within that vision.
It also reflects a wider shift taking place across healthcare, where technology companies are investing heavily in tools designed to help people make lifestyle changes before health problems develop or become more serious.
A pattern is emerging
The Nutrisense acquisition is not an isolated move.
Over the past two years, Dexcom has steadily expanded beyond its traditional role as a CGM manufacturer.
In 2024, the company invested $75 million in Oura and formed a partnership linking CGM data with information from the Oura Ring. More recently, it launched Stelo and has highlighted growing evidence supporting CGM use among people with type 2 diabetes who are not using insulin.
The company has also spoken increasingly about preventative care, earlier intervention and broader access to glucose monitoring.
Viewed together, these developments suggest Dexcom is building a much wider health ecosystem centred around glucose biosensing.
The company's future growth strategy appears to be based not only on selling sensors, but also on helping users understand how lifestyle choices affect health and wellbeing.
Abbott is moving in a similar direction
Dexcom is not alone in seeing opportunities beyond traditional diabetes care.
Abbott's launch of Lingo demonstrated a similar belief that glucose monitoring could have applications in nutrition, lifestyle and metabolic health outside conventional diabetes management.
For many years, Abbott and Dexcom primarily competed for people already living with diabetes. Increasingly, both companies appear to be targeting a much larger audience interested in understanding nutrition, exercise, sleep and overall metabolic health.
That shift could become one of the defining themes of the next decade in diabetes technology.
The competition is no longer solely about who can build the most accurate sensor. It is increasingly about who can provide the most useful insights and support based on the data those sensors generate.
Not everyone is convinced
The growing interest in metabolic health has attracted significant investment, but it has also sparked debate.
Some healthcare professionals question whether glucose monitoring is always necessary for people without diabetes and whether normal glucose fluctuations can sometimes be overinterpreted. Others argue that increased awareness of glucose responses may help people make better-informed decisions about nutrition and lifestyle.
Among CGM users, opinions are similarly mixed.
Many welcome tools that provide more context around blood sugar readings and help explain why certain patterns occur. Others believe the industry's priorities should remain focused on improving affordability, access, sensor performance and user experience.
For people still waiting to access CGM technology, insulin pumps or hybrid-closed loop systems, discussions about metabolic optimisation may feel less pressing than improving access to existing diabetes technologies.
What could this mean for diabetes management?
For current Dexcom users, there is unlikely to be any immediate change.
Dexcom G7, Dexcom ONE+ and existing hybrid-closed loop integrations remain central to the company's business.
Over time, however, the acquisition could influence how CGM information is presented and interpreted. Future developments could include more personalised nutrition recommendations, stronger links between food logging and glucose responses, enhanced meal analysis tools and greater use of AI-powered coaching.
The challenge will be ensuring these features remain genuinely useful.
Many CGM users already receive a substantial amount of information every day. The most successful future platforms are likely to be those that simplify decision-making and help users focus on meaningful insights rather than generating more data.
The next move
Most diabetes technology headlines focus on new sensors, longer wear times or insulin pump integrations. The Nutrisense acquisition feels different because it is not centred on new hardware.
There is no new CGM sensor, transmitter or insertion device being launched. Instead, the focus is on what happens after a glucose reading appears on the screen and how that information can be turned into practical guidance.
For years, CGM manufacturers have competed largely on sensor performance and accuracy. Increasingly, the next stage of competition may centre on helping people understand what to do with the data those sensors generate.
Dexcom's acquisition of Nutrisense suggests the company believes that future could be just as valuable as the sensor itself.
Whether that proves correct remains to be seen. What is becoming increasingly clear, however, is that the world's largest CGM manufacturers are no longer thinking solely about diabetes. They are increasingly investing in nutrition, behaviour change, prevention and metabolic health, and that could have a significant influence on the next generation of CGM technology.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.